TAVO101
As of the edition of 20 October 2026, TAVO101 is a drug known only by a code name: of no established status; acts on TSLP.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 2, 0 stopped early
- Disease areas
- Immune system; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TSLP | Thymic stromal lymphopoietin | Q969D9 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tavotek Biotherapeutics | Lead sponsor of trials | 2022 to now |